The role of PET/CT in the management of head and neck squamous cell carcinoma  by El-Khodary, Mohamed et al.
ORIGINAL ARTICLE
The Egyptian Journal of Radiology and Nuclear Medicine (2011) 42, 157–167
Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comThe role of PET/CT in the management of head and
neck squamous cell carcinoma
Mohamed El-Khodary a,1, Reda Tabashy b,*, Walid Omar c,2, Amr Mousa d,3,
Ahmed Mostafa e,4
a Diagnostic Radiology and Nuclear Medicine Department, Health Center, McGill University, Canada
b Diagnostic Radiology Department, National Cancer Institute, Cairo University, Egypt
c Nuclear Medicine Department, National Cancer Institute, Cairo University, Egypt
d Radiation Oncology Department, National Cancer Institute, Cairo University, Egypt
e Surgical Oncology Department, National Cancer Institute, Cairo University, Egypt
Received 4 March 2011; accepted 15 May 2011
Available online 2 July 2011KEYWORDS
18F-ﬂuorodeoxyglucose
(FDG);
Positron emission tomogra-
phy (PET);
FDG–PET/computed
tomography (FDG–PET/
CT);
Abstract Purpose: To assess the role of positron emission tomography/computed tomography
(PET/CT) with 18F-ﬂuorodeoxyglucose (FDG) in patients with head and neck squamous cell car-
cinoma and to assess the impact of PET/CT on the clinical management.
Patients and methods: Sixty-three patients with pathologically proven head and neck squamous cell
carcinoma had 83 PET/CT and CT examinations. The ﬁrst group includes 45 examinations per-
formed as a pre treatment staging for 45 patients. The second group includes 38 examinations per-
formed for 18 patients who had previous treatment.
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Results: In the ﬁrst group, FDG–PET/CT yielded additional diagnostic information in 44.4% of
patients, with subsequent modiﬁcation of treatment strategy in 11.1% and implementation of fur-
ther curative therapy in 6.6%. Based on the ﬁndings of PET/CT, modiﬁcation of radiotherapy was
performed in 24.6% of patients in this group. In the second group, PET/CT altered further clinical
management in 18.4% patients and induced a change in the planned therapeutic approach in
23.6%.
Conclusion: PET/CT is an imaging modality with high diagnostic performance in the assessment of
head and squamous cell carcinoma, and induced a signiﬁcant change in the management of the
study population.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.
158 M. El-Khodary et al.1. Introduction
Head and neck cancers represent approximately 2–4% of all
malignancies in the United States, with an annual incidence
of 35,720 new cases, 90% of them are squamous cell carcinoma
(1). At diagnosis, accurate staging has a prognostic value and
is important in selecting the appropriate treatment strategy.
After therapy, early detection of recurrence is critical to
achieve an optimal outcome.
Computed tomography (CT) and magnetic resonance
imaging (MRI) are the standard conventional imaging
modalities for evaluation of patients with head and neck
cancer. These tests, however, are based on morphologic
diagnostic criteria, such as nodal size and contrast enhance-
ment patterns that do not always accurately reﬂect the pres-
ence of active malignancy. Although imaging is important
for assessing response after treatment of head and neck can-
cers as well as for early diagnosis of recurrence, the regional
anatomy is distorted by surgery and/or radiation; this makes
the distinction between post-treatment changes and recur-
rence or residual tumor difﬁcult with imaging tests that rely
on the forementioned morphologic criteria. In this speciﬁc
clinical setting, CT and/or MRI have a known limited accu-
racy (2).
Fluorine-18 ﬂuorodeoxyglucose (FDG) positron emission
tomography (PET), a functional imaging modality plays an
increasing role in the assessment of head and neck cancers,
both for primary staging (3) as well as for post-therapy
management (4,5). The use of PET is based on its capabil-
ity to assess the metabolic status of tumors. PET has
proved superior to both CT and MRI in diagnosing and
differentiating recurrence from post radiation effects and
surgical scars in sites of tumors of the head and neck
(6,7). PET is superior to CT and MRI in the detection of
cervical lymph node status in cases of head and neck cancer
(8).
However, PET is limited by the lack of anatomic land-
marks, and the precise localization of suspicious ﬁndings is dif-
ﬁcult due to the low background tracer uptake. In addition,
variable degrees of physiologic and inﬂammatory non can-
cer-related uptake of FDG in the region of the head and neck
mainly after treatment can confound interpretation of suspi-
cious foci.
The combined imaging modality of PET/CT makes it pos-
sible to sequentially acquire PET and CT in a single imaging
session with fusion of clinically signiﬁcant anatomic and met-
abolic data. Preliminary studies have shown that PET/CT im-proves the anatomic localization of FDG-avid abnormalities
and reduces the number of equivocal PET interpretations in
selected tumors of the head and neck (9).
2. Patients and methods
2.1. Patients
Sixty three patients (51 men and 12 women, mean age 58 years)
with head and neck squamous cell carcinoma had 83 combined
FDG–PET/CT and CT examinations at the department of
Diagnostic Radiology and Nuclear Medicine, McGill Univer-
sity Health Centre in collaboration with the National Cancer
Institute, Cairo University between September 2007 and June
2010.
Forty ﬁve PET/CT studies performed as a pre treatment
staging for 45 patients who had not received any previous
treatment. Thirty-eight PET/CT studies performed for 18 pa-
tients who had previous treatment, including 28 studies for
suspected locoregional recurrence, four studies for suspected
distant metastases, and six studies for treatment response to
therapy (Table 1).
To maintain homogeneity of the statistical analysis, we sep-
arated the 45 patients who had not received any treatment and
the PET/CT done for pretreatment staging as one group and
the other 18 patients who previously treated as another group.
2.1.1. First group
In the ﬁrst group, PET/CT study done for American Joint
Committee on Cancer (AJCC) TNM staging and for radio-
therapy planning. At the time of PET/CT imaging, no patients
had clinical or radiologic evidence of distant metastases or syn-
chronous tumors by CT of the head and neck and chest X-ray.
In this group, we studied the diagnostic and therapeutic im-
pact of the PET/CT on the management of the head and neck
squamous cell carcinoma compared with the morphologic CT
examination. Speciﬁcally, we looked for how PET/CT altered
the TNM staging and the treatment plan.
2.1.2. Second group
This group includes the 18 patients who had received previous
treatment. PET/CT done for suspected locoregional recur-
rence, suspected distant metastases, and treatment monitoring.
Thirty-eight post treatment PET/CT studies were performed
on average 8 weeks after completing deﬁnitive radiation
therapy.
Table 1 Patient characteristics.
Characteristics Number %
Mean age 58
Sex
Male 51 80.9
Female 12 19.1
Primary site
Nasopharynx 10 15.9
Oropharynx 31 49.2
Hypopharynx 3 4.7
Oral cavity 8 12.8
Larynx 9 14.3
Other 2 3.1
Indication for PET/CT
Staging 45 54.2
Locoregional recurrence 28 33.7
Response to treatment 6 7.3
Distant metastases 4 4.8
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(range 4–24 months). Biopsy, imaging follow-up (including
PET/CT and CT), and clinical follow-up were all used as
a standard references for determining the presence or ab-
sence of a tumor and the accuracy of the CT and PET/
CT studies.
CT and PET–CT ﬁndings classiﬁed as true positive (TP, po-
sitive imaging study conﬁrmed as presence of cancer), true neg-
ative (TN, normal study with no further evidence of cancer),
false positive (FP, positive imaging study with no evidence of
cancer), or false negative (FN, normal study with further pro-
ven cancer).
2.2. Methods
2.2.1. Imaging
2.2.1.1. FDG–PET/CT. Informed consent for PET/CT was ob-
tained from all patients. Leukocytic count, C-reactive protein
and body temperature were monitored to exclude the presence
of acute inﬂammation.
Patients instructed to fast for 4–6 h prior to scanning.
Blood glucose level was measured prior to injection. Patients
with elevated blood glucose level more than 11 mmol
(200 mg)/dL were not scanned. Patients were rested for a per-
iod of about 60 min in comfortable chair and instructed to
minimize any talking, chewing, swallowing, or movement of
the head, because these activities can inﬂuence muscular up-
take in the masticator muscles, tip of the tongue, face, neck,
and larynx.
PET/CT imaging was performed by the (Discovery STE 16,
General Electric Medical System). Whole body PET and non
contrast-enhanced CT imaging from the skull base to the
upper thigh was performed approximately 1 h after intrave-
nous injection of 8–15 mCi (296–555 MBq) of fuorodeoxyglu-
cose (FDG). A limited breath-holding at normal expiration
was done to avoid motion-artifacts and to match co-registra-
tion of CT and PET images in the area of the diaphragm.
CT was acquired to perform transmission correction for the
PET using the following parameters: 140 kV, 120–240 mAs
and slice thickness 1.25 mm. PET images (axial ﬁeld 90 cm,
slice thickness 1.25 mm, four to ﬁve bed positions/patient,one head and neck position, 5 min/bed position,) were recon-
structed with and without attenuation correction.
The PET scans were corrected for attenuation with coefﬁ-
cients obtained by scaling the CT numbers from the CT scans
to PET energy level (511 kV). Attenuation correction based on
the CT attenuation coefﬁcient, is computed by using VUE
Point HD algorithms. The helical CT scans were reconstructed
into 512 · 512 images with a slice thickness to match those of
the PET scans (1.25 mm).
2.2.1.2. CT. CT was done 2–4 weeks before the PET/CT using
Multislice CT (GE Light speed, VCT 64). CT parameters were;
pitch of 0.969, mAs (autosmart), 120–140 kVp, noise index 12,
ﬁeld of vision (FOV) 25 cm, 2.5 mm slice thickness, interval
1.25, 0 gantry tilt, and matrix 512 · 512. Scan zone was from
the skull base to the aortic arch with sagittal and coronal
reformatting.
A contrast material (Omnipaque, GE healthcare) (70–
80 mL, 1.5 cc/s, and 45 s delay) was intravenously injected in
all patients unless contraindicated because of severe allergy
to the contrast material.
2.2.1.3. Image interpretation. The target of evaluation was set
at the primary head and neck region, neck lymph node region
for the CT and PET/CT examinations, and the whole-body for
the PET/CT examinations. CT and fused PET/CT images
interpreted by radiologist and nuclear medicine physician
who were blinded to the other modality. Each reviewer had ac-
cess to multiplanar reconstructions and to all prior clinical and
radiologic data, including prior PET/CT if present.
For the visual and semi-quantitative interpretation of head
and neck PET/CT scans, metabolically active foci (standard-
ized uptake value (SUV) >3) in the lymph drainage regions
were assessed to determine whether these were consistent with
lymph nodes disclosed by morphological PET/CT and whether
subsequent nodal upstaging or downstaging was necessary
compared with the morphometric diagnosis. In morphometric
terms, a cervical LN was considered to be involved if it showed
rim or heterogeneous enhancement, or if it measured 10 mm or
more in the short axis, regardless of enhancement pattern (10).
Visual and semi-quantitative interpretation of the whole-
body PET/CT scans (SUV>3) performed to establish how of-
ten PET/CT revealed metabolically active foci in the infracla-
vicular region that were consistent with morphological PET/
CT ﬁndings indicative of distant metastases or a simultaneous
second primary tumor.
In the ﬁrst group, all PET/CT ﬁndings were compared with
pre-treatment staging in terms of TNM classiﬁcation to assess
PET/CT diagnostic and therapeutic impact. In the second
group, the PET/CT ﬁndings were compared with the standard
of references.
2.2.2. Standard of reference
Histological results used as a standard reference in the ﬁrst
group. The following criteria were accepted as standard of ref-
erence in the second group: (a) histopathological ﬁndings; (b)
obvious clinical ﬁndings; (c) the combination of negative clin-
ical ﬁndings, negative ﬁndings of other imaging studies, or neg-
ative follow-up ﬁndings; (d) resolution of the apparent
abnormalities at subsequent PET/CT studies without interven-
ing therapy together with negative clinical follow-up ﬁndings;
Table 2 Incidence of distant metastases and second primary tumors as revealed by PET/CT in the 45 patients.
Distant metastases Conﬁrmed by imaging
Patient 1 Liver and spleen 1
Patient 2 Osseous 1
Patient 3 Lung and mediastinal L.Ns 1
Patient 4 Osseous 1
Patient 5 Abdominal L.Ns 1
Second primary Conﬁrmed by pathology
Patient 1 Rectal carcinoma 1
Patient 2 Rectal carcinoma 1
Patient 3 Gastric carcinoma 1
Figure 1 Sixty-eight years old male with squamous cell carcinoma of the tongue base. Fused PET/CT images showing left tongue base
mass of increased FDG with pathological bilateral level II lymph nodes. Contrast enhanced CT image showing pathological necrotic left
level II lymph node. Subcentemetric right level II lymph node corresponding to the PET/CT ﬁnding, not pathological by CT criteria.
Table 3 Diagnostic impact of the PET/CT in the 45 patients.
Diagnostic impact of PET/CT Number (N) %
FDG–PET/CT patients 45 100
Diagnosis of second primary 3 6.6
Diagnosis of metastases 5 11.1
Nodal upstaging 12 26.6
Nodal downstaging 3 6.6
Total 23 51.1
Diagnostic impact in terms of number of patients 20 44.4
160 M. El-Khodary et al.and (e) the combination of positive clinical ﬁndings at the time
of PET/CT and the resolution of the tumor after radiotherapy
and chemotherapy.
In patients with suspected tumor recurrence, the ﬁnal diag-
nosis was conﬁrmed either by biopsy or clinically. Active
malignancy was excluded by negative biopsy, negative re-
peated imaging results, or negative follow-up. Findings suspi-
cious for the presence of distant metastases, or second primary
cancers were conﬁrmed by either histological or by combina-
tion of additional imaging studies and clinical follow-up.
Table 4 Therapeutic impact of the PET/CT in the 45 patients.
Therapeutic impact of PET/CT Number (N) %
FDG–PET/CT patients 45 100
Strategy change 5 11.1
Further curative 3 6.6
Radiotherapy modiﬁcation 11 24.4
Total 19 41.1
Therapeutic impact in terms of number
of patients
19 41.1
Figure 2 Fifty-six years old male with squamous cell carcinoma of
necrotic left level II lymph node and right level II small one. Fused P
pathological right level II lymph node. The left side lymph node is n
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dictive value (PPV), negative predictive value (NPV), and
accuracy were calculated for both CT and PET/CT. The differ-
ences in performance of both modalities were compared with
the Chi-Square tests including Pearson Chi-Square and
Fisher’s Exact tests (12–14) as appropriate, with P values less
than 0.05 considered to be statistically signiﬁcant. Measure-
ment of agreement is also calculated using the Kappa values
(15).
2.2.4. End point
For the ﬁrst group, the end point was to assess the diagnostic
impact of PET/CT compared with the pre-treatment morpho-
logical imaging. A second end point was to determine the
therapeutic impact of FDG–PET/CT in terms of changes to
the initial treatment plan or modiﬁcations to radiotherapy.
Nodal upstaging or downstaging as suggested by PET/CT2.2.3. Statistical analysis
For the ﬁrst group, descriptive statistics were calculated using
medCalc version 7.0.0.2 (11). Because this was an exploratory
study, no inferential statistical methods were used.the right tonsil. Contrast enhanced CT image showing pathological
ET/CT images showing right tonsillar mass of increased FDG and
ot depicted by the PET/CT but was positive by pathology.
Table 5 Diagnostic accuracy of PET/CT and CT, study-based
analysis.
PET/CT (%) CT (%) P-value
Sensitivity 92.6 74.1 0.063
Speciﬁcity 90.9 27.3 <0.001
PPV 96.2 71.4 0.009
NPV 83.3 30.0 <0.001
Accuracy 92.1 60.5 0.003
Table 6 Diagnostic accuracy of PET/CT and CT, according
to indication for study.
PET/CT (%) CT (%)
Treatment response Sensitivity 85 86
Speciﬁcity 98 35
PPV 97 73
NPV 70 53
Accuracy 90 75
Locoregional disease Sensitivity 90 70
Speciﬁcity 89 31
PPV 92 70
NPV 90 60
Accuracy 87 34
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modiﬁed in terms of volume and dose by adapting the boost
volume to metabolically active foci while simultaneously inten-
sifying the dose in these areas.
For both groups, the discovery of distant metastases
prompted revision of the initial treatment strategy and inten-
tion from curative to palliative. Diagnosis of a simultaneous
second primary tumor necessitated formulation of an individ-
ual treatment strategy, principally along curative lines, once
metastatic spread had been excluded.
In the event of solitary infraclavicular ﬁndings and a sus-
pected second primary tumor, ﬁndings were conﬁrmed by
histology and in cases with multiple infraclavicular foci and
suspected metastases further imaging clariﬁcation was per-
formed. After appropriate beneﬁt-risk analysis, metabolically
active cervical LNs were not subjected to further histological
assessment.
3. Results
3.1. First group
3.1.1. Diagnostic impact
PET/CT detected distant metastases for the ﬁrst time in ﬁve
(11.1%) patients. A second primary tumor was detected in
three (6.6%). Active FDG uptake was detected in the rectum
in one patient (proved adenocarcinoma), and FDG uptake in
the rectum and the liver (proved rectal adenocarcinoma with
liver metastasis) in the second patient. The third patient had
gastric fundal adenocarcinoma with liver metastasis (Table 2).
Compared with the morphological CT ﬁndings, nodal sta-
tus based on metabolic activity was upstaged in 12 (26.6%)
(Fig. 1) and downstaged in three (6.6%) patients. Compared
with the CT ﬁndings, the total TNM staging changed in 23
(51.1%) patients. Upstaged in 19 (42.2%) and downstaged in
four (8.8%) patients (Table 3).
On the basis of the information yielded by PET/CT, treat-
ment strategy was modiﬁed from curative to palliative in ﬁve
(11.1%). Because of the diagnosis of a second primary, three
(6.6%) patients received additional curative therapy as part
of an interdisciplinary treatment strategy. In the light of
PET/CT, changes in the nodal status based on metabolic activ-
ity resulted in modiﬁcation of radiotherapy volume and dose
in 11 (24.4%) patients. Overall, PET/CT resulted in treatment
change or radiotherapy modiﬁcation in 19 (41.7%) patients
(Table 4).
3.2. Second group
3.2.1. Diagnostic impact
Thirty-eight CT studies were reviewed. CT deﬁned 28 (73.7%)
studies as positive and 10 (26.3%) as negative. There were 20
true positive, eight false positive, three true negative, and seven
false negative studies. The Pearson Chi-Square value was 0.007
and P value 0.932 and the P value by Fisher’s Exact was 1.0.
The Kappa value was 0.014 with P value 0.932 denoting very
week agreement between the CT and the standard of
references.
Thirty-eight PET/CT studies were reviewed. PET/CT de-
ﬁned 26 (68.4%) studies as positive and 12 (31.6%) as nega-
tive. There were 25 true positive, one false positive, 10 truenegative, and two false negative studies. The Pearson Chi-
Square value was 25.222 and P< 0.001 and the P value by
Fisher’s Exact was <0.001. The Kappa value was 0.813 with
P value <0.001 denoting strong agreement between the
PET/CT and the standard of references.
The false positive case on PET/CT was patient with squa-
mous cell carcinoma of the nasopharynx, with mild uptake
at level II lymph node that was thought to be nodal recurrence,
proved negative on biopsy.
One false negative case on PET/CT is seen in patient with
recurrent tonsillar carcinoma after resection and neck dissec-
tion, showing a necrotic lymph node with no activity. Biopsy
showed metastatic SCC (Fig. 2). The other false positive case
was a base of tongue carcinoma after radiotherapy and che-
motherapy, showing mild residual uptake thought to repre-
sent residual tumor and resolved on follow-up with no
treatment.
The diagnostic accuracy of the CT and PET/CT for the
study-based statistical analysis is shown in (Tables 5 and 6).
3.2.2. Therapeutic impact
PET/CT altered further clinical management in seven (18.4%)
patients. Biopsy or ﬁne needle aspiration had been planned
based on clinical examination and radiologic data suspicious
of recurrence and was canceled because of negative PET/CT
results (Fig. 3).
PET/CT induced a change in the planned therapeutic ap-
proach in nine (23.6%). One patient had initially supraglottic
SCC was diagnosed to have distant pancreatic and liver metas-
tases, so treatment plan changed from curative to palliative.
Two patients were diagnosed to have second primary adeno-
carcinoma of the rectum, so proper rectal carcinoma manage-
ment was initiated.
Figure 3 Fifty-nine years old male with squamous cell carcinoma of the tongue base. Post glossectomy and myocutaneous ﬂap with
suspicious left sided local post operative recurrence on CT. PET–CT revealed no evidence of FDG uptake to suggest recurrence. Patient
was disease free on further follow-up.
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area inside an edematous region in six patients (three larynx,
two nasopharynx, and one oropharynx) decreased the chances
for tissue sampling errors and avoided damage to non malig-
nant tissue. Biopsy was positive for malignancy in all of the
six patients.
4. Discussion
The use of FDG as a tracer is based on Warburg’s discoveries
that cancer cells are partial anaerobes and ferment sugar by
producing lactate; thus a considerable proportion of the energy
developed by cancer cells is derived not from oxidation but
from fermentation (16). The reduced energy yield by compar-
ison with oxidation is compensated for by an increase in glu-
cose metabolism. Glucose uptake here is dependent on the
expression of glucose transporters, on the activity of hexokin-
ases that regulate entry into the glycolytic pathway, and on cell
proliferation of the tissue studied. Tissue hypoxia activates thetranscription of glucose transporters via hypoxia-inducible fac-
tor (17).
Imaging is an important clinical tool in the evaluation of
patients with head and neck cancer. CT modalities rely on
morphologic criteria such as nodal size and contrast enhance-
ment pattern that does not always accurately reﬂect the pres-
ence of active malignant conditions. The reported sensitivity,
speciﬁcity, and accuracy of CT for diagnosis of cervical nodal
metastases were 88%, 86%, and 87%, respectively (18), and
speciﬁcity dropped further when the 10 mm size criterion was
used, to 39% for CT and 48% for MRI (19).
FDG–PET plays an increasing role in the diagnosis and
management planning of head and neck cancer. Hybrid
PET/CT has promoted the ﬁeld of molecular imaging in head
and neck cancer. This modality is particularly relevant in the
head and neck region, given the complex anatomy and variable
physiologic FDG uptake patterns. The vast majority of PET/
CT applications in head and neck cancer related to head and
neck squamous cell carcinoma. Clinical applications of PET/
164 M. El-Khodary et al.CT in the head and neck cancer include diagnosis of distant
metastases, detection of synchronous second primaries, detec-
tion of carcinoma of unknown primary and detection of resid-
ual or recurrent disease. Emerging applications are precise
delineation of the tumor volume for radiation treatment plan-
ning, monitoring treatment, and providing prognostic
information.
Accurate staging at the time of diagnosis is the most
important factor for treatment planning and determination
of prognosis. One attractive feature of PET as a modality
for initial TNM staging is that it covers most of the body
within single study. PET therefore provides information on
the primary tumor, nodal metastases, distant metastases,
and potential second primary carcinomas. A literature sur-
vey on the use of PET in head and neck cancer compared
to CT indicates that PET has a higher sensitivity (87% ver-
sus 62%) and speciﬁcity (89% versus 73%) for cancer stag-
ing. Addition of PET/CT to the initial staging of patients
with head and neck cancers has a measurable impact on
the treatment selection (20).
According to the data in the published literature, the inci-
dence of distant metastases at the time of the initial diagnosis
of head and neck cancers are low, with reported ﬁgures rang-
ing from 1.6% to 4.2%. Ultimately this is the basis for the rec-
ommendation from the national comprehensive cancer
network (NCCN) that systemic staging should be limited to
chest X-ray and optional chest CT. This minimal staging is
usual in clinical practice and has been applied in several pro-
spective randomised clinical studies (21).
In a retrospective analysis of 600 patients with head and
neck cancer, Dietl et al. detected distant metastases in only
4.8% of patients at initial cancer diagnosis, in 19% of patients
during the further course of illness, and in 24.2% of patients in
stage IV disease; the steep rise in metastatic disease during the
ﬁrst 12 months suggested a clinically silent process of metasta-
sis at an earlier point in time (22).
The use of additional pre-treatment diagnostic modalities
with increased sensitivity results in a higher detection rate
for metastatic disease. Thus, at the time of the initial diagnosis,
distant metastases are detectable in 17% of patients by routine
chest CT, and in 21% of patients by extended ﬁeld PET (23).
The role of PET for staging of distant metastases in head
and neck cancer is acknowledged as one of the most powerful
indication. There is a general agreement that PET is indicated
for initial staging when there is suspicious of distant metastases
and synchronous second tumor. The incidence of distant
metastases increases with locally advanced (T3–T4), N2, or
N3 disease, extracapsular extension of the lymph node disease,
and perineural invasion (24).
Distant metastases considerably limit overall survival,
which may range from 4.3 to 8.2 months from the time when
metastatic disease is ﬁrst diagnosed. There is no adequate sal-
vage therapy, and the Karnofsky performance status is crucial.
This tends to be adversely affected by the toxicity of inappro-
priate curative therapy, and it is therefore vital for the initial
treatment strategy to be deﬁned correctly (25).
In the ﬁrst group of our patients, FDG–PET/CT detected
distant metastases for the ﬁrst time in ﬁve (11.1%) patients.
On the basis of the information yielded by PET/CT, treatment
strategy was modiﬁed from curative to palliative therapy. In
the second group of our patients, one patient had initially
supraglottic SCC was diagnosed to have distant pancreaticand liver metastases, so treatment plan changed from curative
to palliative one. In Dietl et al. study, PET/CT detected six
(17.1%) out of the 35 included patients to have distant metas-
tases and all are conﬁrmed by further imaging (26). In Gordin
et al. study, PET/CT diagnosed distant metastases in seven out
of the 90 patients, which changed the treatment protocol from
curative to palliative and ruled out distant metastases sus-
pected by CT in 10 patients, so they received deﬁnitive treat-
ment (27).
The incidence of second primary tumors with simultaneous,
synchronous or metachronous manifestation is reported to be
as high as 16%; in most cases these second malignancies are
associated with exposure to harmful agents, and include bron-
chial carcinomas, other head and neck malignancies or esoph-
ageal carcinomas. PET and PET/CT have proven useful for
detection of second primary tumors in the head and neck
and elsewhere in the body in patients with previously treat-
ment head and neck SCC being evaluated for recurrence (28).
In our ﬁrst group, second primary tumor detected in three
(6.6%) patients. Active FDG uptake was detected in the rec-
tum in one patient (proved adenocarcinoma), and in the rec-
tum and the liver (proved rectal adenocarcinoma with liver
metastasis) in the second patient. The third patient had gastric
fundal adenocarcinoma with liver metastasis. Because of the
diagnosis of a second primary, the three patients received
additional curative therapy as part of an interdisciplinary
treatment strategy. In the second group, two patients were
diagnosed to have second primary adenocarcinoma of the rec-
tum, so proper rectal carcinoma management was initiated.
Fleming et al. described 123 patients with head and neck can-
cers initially staged with FDG–PET/CT and the prevalence of
second cancers in their population was 4.9% (29). Goerres
et al. found four second primaries in 34 patients with oral
SCC, resulting in prevalence of synchronous primaries of
12% (30). In Dietl et al. study, PET/CT detected four
(11.4%) out of the 35 included patients to have second prima-
ries, two bronchial carcinoma and two esophageal carcinoma,
all conﬁrmed by pathology (26).
Lymph node metastases reduce survival by 50%, with the
prognosis in this context depending on factors such as the num-
ber of lymph nodes inﬁltrated, level of inﬁltration, extracapsular
spread, and the resectability (31). Macroscopic LN metastases
require surgical resection, or they should be included in the
boost volume and irradiated with a tumoricidal dose of at least
70 Gy. Otherwise the result is relatively under-dosing with the
risk of tumor progression or local recurrence (32). As with dis-
tant metastases, there is also no adequate salvage therapy avail-
able for local recurrence, and the two year survival rate
following treatment for recurrence is 25% (33).
The diagnosis of inﬁltration and hence also the deﬁnition of
target volume is usually based on criteria provided by morpho-
logical imaging techniques. Their sensitivity and speciﬁcity in
the evaluation of the N0 neck range from 14% to 83% and
from 78% to 100%, respectively (34). The sensitivity and spec-
iﬁcity of PET/CT in the assessment of cervical LNs range from
80% to 90% and from 88% to 100%, respectively, and are
therefore superior to those of morphological imaging tech-
niques (35).
In our study’s ﬁrst group, compared with the morphologi-
cal CT ﬁndings, nodal status based on metabolic activity by
PET/CT was upstaged in 12 (26.6%) (Fig. 1) and downstaged
in three (6.6%) patients. The total TNM staging changed in 23
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four (8.8%) patients. Koshy et al. enrolled 36 patients and
found that PET/CT fusion altered the TNM stage in 38%
and clinical stage in 14% of their patients (36). A study by
Dietl et al. for initial staging for head and neck cancer in 35
patients, nodal upstaged in 12 (34.3%), and nodal downstaged
in eight (22.9%) patients (26).
Comparing our results to the Dietl et al. study, on the basis
of the information yielded by PET/CT, treatment strategies
were modiﬁed from curative to palliative in ﬁve (11%) com-
pared to six (17.1%) patients because of the diagnosis of dis-
tant metastases. Because of the diagnosis of second primary
tumor added further curative treatment for three (6.6%) pa-
tients compared to two (5.7%) patients. The changes in nodal
status based on metabolic activity results in modiﬁcation of
radiotherapy volume and dose in 11 (24.4%) patients com-
pared to 20 (57.1%) patients in Dietl et al. study. Overall,
PET/CT resulted in treatment change or radiotherapy modiﬁ-
cation in 19 (41.7%) patients compared to 23 (65.7%) patients
in Dietl et al. study (26).
Surgery and radiation therapy alter the normal head and
neck anatomy. Treatment-related edema, ﬁbrosis, inﬂamma-
tion, and scarring are limiting factors that further hamper
the performance of physical examination and CT or MRI
imaging in the diagnosis of recurrent head and neck cancer.
Numerous studies have shown that PET/CT can detect resid-
ual or recurrent disease with more accuracy than conventional
imaging ranging from 92% to 97% (27).
In our study, the diagnostic accuracy of PET/CT is signiﬁ-
cantly superior to the CT accuracy in patients with head and
neck squamous cell carcinoma for assessment of treatment re-
sponse and recurrent disease, with sensitivity, speciﬁcity, PPV,
NPV and accuracy of 92.6%, 90.9%, 96.2%, 83.3%, and
92.1%, respectively, for PET/CT, and 74.1%, 27.3%, 71.4%,
30.0%, and 60.5%, respectively, for CT. Gordin et al. reported
sensitivity, speciﬁcity, PPV, NPV, and accuracy 89%, 95%,
94%, 90%, and 92%, respectively, for PET/CT, compared
with 92%, 18%, 51%, 71%, and 54%, respectively, for con-
ventional cross sectional imaging (27).
Klabbers et al. reviewed studies published between 1994
and early 2003 regarding the utility of 18F-FDG PET for detec-
tion of residual and recurrent head and neck cancers after
radiotherapy. The results showed better sensitivity of the
18F-FDG PET (86%) and speciﬁcity (73%) compared with
CT and/or MRI sensitivity (56%) and speciﬁcity (59%),
respectively (37).
Ha et al. study included 108 patients and found that 18F-
FDG PET/CT detected persistent or recurrent head and neck
SCC with a sensitivity of 82%, a speciﬁcity of 92%, PPV of
64%, NPV of 97%, and an overall accuracy of 90% (38).
In our study, the signiﬁcantly lower speciﬁcity for CT
(27.3%) as compared with PET/CT (90.9%) supports the pre-
vious reports that showed the low yield of CT in the evaluation
of locoregional recurrence of the head and neck cancer (39).
The inability of the CT to distinguish between the post treat-
ment edema and the local recurrence is the cause of the eight
false positive studies in our study (Fig. 3). A positive PET/
CT accurately guides biopsy to the hypermetabolic foci in an
edematous and scared region as demonstrated in six patients
and thus achieved two goals; decrease sampling errors, and less
damage to normal but edematous structures.PET/CT has a high impact on patient care in the head and
neck cancers. Ha et al. reported that PET/CT altered the treat-
ment plan in 31% of the patients with primary head and neck
SCC. The treatment plan was modiﬁed in 24% of our second
group patients. Most of them had advanced stages III and IV
disease that require a combined therapy approach. Accurate
staging and early detection of recurrence can improve the out-
come of these patients (38).
Although biopsy is the gold standard for diagnosis of recur-
rence, it can cause additional edema, pain, chondroradionecro-
sis, additional costs, and emotional stress (40). In our study,
long term clinical follow-up was the gold standard in this clin-
ical scenario and results in 10 PET/CT studies deﬁned as true
positive and two false positive compared to three true negative
and seven false positive for CT. One PET/CT false negative
was normal in CT scan, the other case had necrotic lymph
node that did not show FDG uptake but was positive for
metastasis on biopsy (Fig. 2). Of the 10 patients, seven were as-
sessed for tumor recurrence, two for treatment response, and
the other one for distant metastasis. Current results indicate
therefore that in patients with a negative PET/CT study, a
biopsy can be at least temporarily postponed unless there is
a high clinical suspicion for recurrent disease.
The utility of anatomical imaging in the post treatment sit-
uation is limited because of ﬁbrosis, tissue edema, and anatom-
ical distortion. The early detection of residual or recurrent
head and neck cancer following radiation therapy and/or che-
motherapy poses a diagnostic challenge. A survey of the liter-
ature showed that 18F-FDG PET is the most sensitive non
invasive modality presently available for differentiating post
treatment changes from residual or recurrent disease (41).
Ong et al. demonstrated in their study that included 65 pa-
tients that PET/CT has high negative predictive value and
speciﬁcity (87% and 89%, respectively.) for excluding residual
locoregional disease after chemoradiotherapy and that neck
dissection may be omitted safely in patients without lymphad-
enopathy, while in patients with residual lymphadenopathy, a
lack of abnormal 18F-FDG uptake in these nodes also excludes
viable tumor with high certainty but still further assessment is
needed (40). In our study PET/CT had a negative predictive
value 83.3% and speciﬁcity 90.9%, respectively.
PET and PET/CT have a high sensitivity and moderate
speciﬁcity for detecting recurrent disease at the primary tumor
site, regional lymph node metastases, and distant metastases.
Wong performed a meta-analysis on the studies published be-
tween 1999 and 2002 that showed relatively high sensitivity
(84–100%) and moderate speciﬁcity (61–93%) regarding the
18F-FDG PET in recurrent HNSCC (42).
The tumor delineation by PET/CT compared with the
pathology was investigated by Halpern et al. who included
49 patients in his study. A patient-by-patient analysis yielded
a sensitivity of 88%, a speciﬁcity of 78%, and an accuracy
of 86% for PET/CT compared to the pathology (43).
5. Conclusion
PET/CT is an imaging modality with high diagnostic perfor-
mance in the assessment of head and squamous cell carcinoma,
and induced a signiﬁcant change in the management of the
study population. In the ﬁrst group, FDG–PET/CT yielded
166 M. El-Khodary et al.additional diagnostic information in 44.4% of patients, with
subsequent modiﬁcation of treatment strategy in 11.1% and
implementation of further curative therapy in 6.6%. Based
on the ﬁndings of PET/CT, modiﬁcation of radiotherapy
was performed in 24.6% of patients in this group. In the sec-
ond group, study-based analysis results in PET/CT sensitivity
92%, speciﬁcity 90.9%, positive predictive value 96.2%, nega-
tive predictive value 83.3%, and total accuracy 92.1%, com-
pared with 74.1%, 27.3%, 71.4%, 30.0%, and 60.5% for
CT, respectively. PET/CT altered further clinical management
in 18.4% patients and induced a change in the planned thera-
peutic approach in 23.6%.
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